Sex differences in obstructive sleep apnoea

Maria R. Bonsignore [1,2], Tarja Saaresranta[3,4] and Renata L. Riha[5,6]

Number 6 in the Series "Sleep Disordered Breathing"
Edited by Renata Riha and Maria Bonsignore

Affiliations: [1]PROMISE Dept, UOC of Pneumology, University of Palermo, Palermo, Italy. [2]Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, Italy. [3]Division of Medicine, Dept of Pulmonary Diseases, Turku University Hospital, Turku, Finland. [4]Sleep research Centre, Dept of Physiology, University of Turku, Turku, Finland. [5]Dept of Sleep Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK. [6]Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.

Correspondence: Renata L. Riha, Dept of Sleep Medicine, Royal Infirmary of Edinburgh, 51 Little France Crescent, EH16 4SA, Edinburgh, UK. E-mail: rriha1@exseed.ed.ac.uk

ABSTRACT Obstructive sleep apnoea (OSA) and obstructive sleep apnoea/hypopnoea syndrome (OSAHS) have long been considered predominantly male-related conditions. The clinical presentation of sleep disordered breathing in females differs from males and can vary with age and physiological status, *e.g.* menopause and pregnancy. Overall, females appear to be more symptomatic, with lower apnoea–hypopnoea index scores compared to males. Furthermore, they appear to have more prolonged partial upper airway obstruction, and may report insomnia as a symptom of OSAHS more frequently. As a consequence of these differences in clinical presentation, females with sleep disordered breathing are often underdiagnosed and undertreated compared to males. This review is aimed at discussing the epidemiology, clinical presentation, pathophysiology and hormonal and metabolic differences in females who present with OSA/OSAHS in comparison to males.

Epidemiology of obstructive sleep apnoea

The most prevalent form of sleep disordered breathing in industrialised societies is obstructive sleep apnoea (OSA) [1]. OSA is characterised by repetitive collapses (apnoeas) or near collapses (hypopnoeas) of the upper airway during sleep, resulting in intermittent hypoxaemia and increased sympathetic arousal. When symptoms of daytime dysfunction and other neurological impairment are directly attributed to the apnoeas and hypopnoeas in sleep, the disorder is known as obstructive sleep apnoea/hypopnoea syndrome (OSAHS) [1–3].

The apnoea–hypopnoea index (AHI) can be used to assess severity of the sleep disorder when an electroencephalographic measure of sleep is available. Daytime sleepiness is usually recorded by a thorough clinical history, but is also frequently recorded in both practice and in research studies using the Epworth Sleepiness Scale (ESS) [4]; a score of ⩾11 out of 24 is considered consistent with excessive daytime sleepiness. Unfortunately, the ESS does not correlate well with objective measures of daytime sleepiness [5].

Thus, the epidemiology of OSA and OSAHS can vary significantly in the population depending on definitions used for the nocturnal breathing pauses and any resulting daytime sleepiness/impairment. Additionally, the prevalence of sleep disordered breathing will vary according to age and sex [1–3].

The most frequently cited study in respect of OSA and OSAHS prevalence in a mostly white, mid-American cohort of people demonstrated that 24% of males (n=325) and 9% of females (n=250) had an AHI ⩾5 events·h^{-1} of sleep [6]. However, when sleepiness was factored in as causally related to the AHI, the prevalence fell to 4% in males and 2% in females. Several population prevalence studies since then have quoted mean prevalences of OSA of 27.3% in males (range 9–86%) and 22.5% in females (3.7–63.7%) and mean (range) prevalence of OSAHS of 6% (3–18%) in males and 4% (1–17%) in females [7, 8].

Consequently, and unsurprisingly, OSA/OSAHS has thus been considered a male disease, with male:female ratios ranging from 3:1 to 5:1 in the general population and from 8:1 to 10:1 in selected clinical populations [9]. Despite this, females now represent up to 40–50% of presentations at sleep clinics [10].

Clinical presentation

Failure to recognise the distinct clinical presentation and sex-specific differences in sleep studies may lead to underdiagnosis or misdiagnosis of OSA/OSAHS in females [11, 12].

Females are less likely to report snoring (males have higher snoring intensity by comparison [13]) or witnessed apnoeas. Females are more likely to complain of daytime fatigue, lack of energy, insomnia symptoms, morning headaches, mood disturbances and nightmares compared to males [11, 12]. This "atypical" clinical presentation at least partly explains the fact that female patients are diagnosed with OSA/OSAHS at older ages and with higher body mass index (BMI) than males [11, 12]. Females seem to have greater impairment of quality of life and higher healthcare expenditure compared to males with similar AHI levels [14–19]. In addition, females with OSA report a higher rate of impaired work performance, sick leave and divorce compared to females without OSA, identical in age and visceral fat mass; this kind of association has not been found among males [14–19]. OSA in females is associated with an increased risk of sickness absence compared to males with OSA, even 5 years *versus* 1 year prior to diagnosing OSA [20]. A prospective study of 74 543 cases of OSA from the Swedish Patient Register matched with 371 592 non-cases, demonstrated during a 5-year follow-up period a higher risk for disability pension among females with OSA compared to males with OSA [19].

Compared to males, OSA/OSAHS typically manifests in females as a lower AHI, shorter apnoeic episodes, lower proportion of supine OSA and clustering of apnoea during rapid eye movement (REM) sleep [11]. However, in females, the longest apnoeas are associated with a more severe oxygen desaturation [21]. Respiratory events during sleep are less frequently associated with complete upper airway collapse in females than in males [11]. However, despite less-severe OSA in terms of AHI, females are not less symptomatic compared to males, but report sleepiness at relatively low levels of AHI [22]. Therefore, especially in females, AHI alone is not a sufficient criterion for clinical severity of OSA. The severity should be specified with objective polysomnography (or cardiorespiratory polygraphy) findings (AHI/respiratory effort index plus flow-limitation) and subjective daytime sleepiness with functional disability. In females with low AHI, a continuous positive airway pressure (CPAP) trial should be symptom-driven [23, 24].

What might explain this apparent discrepancy between AHI and symptoms in females particularly? In females, upper airway obstruction often manifests as subcriterion events (snoring, flow limitation or prolonged partial upper airway obstruction) [25–28]. Arousals induce less ventilatory instability in females, thereby protecting them from OSA. Prolonged episodes of partial upper airway obstruction [25–28] typically appear in slow-wave sleep and are associated with increased carbon dioxide (CO_2) levels [29–31]. Importantly, prolonged partial upper airway obstruction is far more common than "conventional" sleep apnoea in females [32]. Furthermore, hypothyroidism is more prevalent in females than in males, which *per se* may induce OSA. Prolonged partial upper airway obstruction is related to increased respiratory resistance [33], which is characterised by increase in end-tidal CO_2 [34] and transcutaneous CO_2 [29, 30]. Prolonged partial obstruction with increased CO_2 during sleep may contribute to a different symptom profile in females. This is supported by the finding that in females, excessive daytime sleepiness and

daytime fatigue associate with habitual snoring independent of AHI, age, obesity, smoking or sleep parameters [26]. Correction of prolonged flow limitation with CPAP treatment is associated with a higher attentiveness and a higher efficiency in normalising daytime vigilance than when eliminating only apnoea, hypopnoea and snoring [35]. Hypercapnia is associated with electroencephalogram (EEG) slowing and daytime sleepiness in OSA [36], and CPAP treatment corrects the EEG slowing and alleviates daytime sleepiness [37].

Comorbidities

The AHI seems to underestimate systemic inflammation in females [38]. REM predisposition of AHI is associated with increased intima thickness, even in females with no or mild OSA and normal non-REM AHI [39]. In a Finnish longitudinal population-based study with up to 25-year follow-up data on almost 37 000 individuals, OSA independently increased the risk for coronary heart disease and type 2 diabetes mellitus, particularly in females [40]. Of importance, clinical OSA phenotypes with insomnia-like symptoms are more prevalent in females than in males [41], and despite less severe sleep disordered breathing in terms of AHI, those OSA phenotypes have a higher burden of cardiovascular, pulmonary and psychiatric comorbidity and lower CPAP adherence compared to patients with the traditional sleepy phenotype [42]. A high prevalence of particularly cardiovascular comorbidity among patients with insomnia-like symptoms seems to be linked with nocturnal hypoxaemia [41]. However, the data are not consistent, and some studies suggest a higher risk of cardiovascular comorbidity [43] and type 2 diabetes [44] in males with OSA.

Menopause

There is paucity of data regarding possible differences in clinical presentation of OSA/OSAHS between pre- and postmenopausal females. In postmenopausal females, symptoms of OSA may easily be neglected or interpreted as menopausal symptoms. Prevalence of OSA/OSAHS in females doubles after menopause [45–47] independently of age and BMI [46], the peak being at age 65 years, 10 years later than in males [45]. Less hyperpnoea after episodic hypoxia and more stable respiratory effort in non-REM sleep in response to hypercapnia and arousals might protect premenopausal females from OSA [48]. During menopausal transition, respiratory drive decreases [49]. Increased arousals and increased soft tissue collapsibility predispose to respiratory instability and aggravate upper airway obstruction. Recent data suggest that severe vasomotor symptoms may be an independent risk factor for OSA [50]. Premenopausal females and females who use hormone therapy have lower apnoeic thresholds than postmenopausal hormone therapy non-users and males [48] resulting in more stable breathing. Furthermore, in a large follow-up study, the hazard ratio for OSA in females with surgical menopause was 1.27 compared with females with natural menopause, independently of age at menopause [51]. The increased OSA risk due to surgical menopause persisted for over 15 years into the postmenopausal period and was more pronounced in lean females and those who had never used menopausal hormone therapy. Higher physical activity was associated with lower OSA risk.

Pregnancy

Sleep disordered breathing in pregnancy is thought to play a role in maternal and fetal outcomes. The prevalence of OSA/OSAHS in pregnancy, diagnosed by polysomnography or polygraphy is not well defined, and there is a lack of large prospective studies. Potential risk factors for sleep disordered breathing in pregnancy include a reduction in upper airway size due to increased fluid retention and weight gain; nasal obstruction due to increased oedema from high oestrogen levels, nasal congestion or rhinitis; and reduced functional capacity and residual volume due to the lung mechanics in pregnancy [52–54]. Minute ventilation increases, and sleep may be fragmented depending on the level of discomfort and the trimester in which sleep is recorded [52].

Conversely, there are protective factors for OSA in pregnancy, including high progesterone levels, leading to increased upper airway dilator muscle activity; enhanced chemoreceptor responsiveness; and improved delivery of oxygen with a right-shifted Severinghaus curve and increases in heart rate and stroke volume [54]. Females tend to spend less time in the supine position, particularly during the third trimester [52].

Studies that have been conducted in pregnancy report that snoring steadily increases during the three trimesters [55]. The prevalence of snoring has been estimated to be between 10% and 46% [55]. This wide range can be attributed to variability in study design and the use of both objective and self-report measures. Longitudinal studies have shown that habitual snoring (three or more nights per week) increases from 7–11% in the first trimester to 16–25% in the third trimester [55, 56]. In pregnant females, the prevalence of OSA with an AHI $\geqslant 5$ events·h^{-1} has been reported to be 3.6% in early pregnancy and 8.3% in mid-pregnancy; however, studies have been limited to small populations [57]. Snoring/OSA during pregnancy has been associated with pregnancy-induced hypertension and intrauterine growth retardation

as well as hypertension and diabetes [58]. Currently, there are no published randomised controlled trials of treatment of OSA/OSAHS in pregnancy, but observational studies have suggested that treatment can reduce blood pressure and improve pregnancy outcomes [52]. In summary, what comprises clinically significant sleep disordered breathing in pregnancy has not been defined. As technology advances rapidly, the ability to identify upper airway flow limitation will improve and the use of other sensors to define what may be clinically impactful sleep disordered breathing for both the mother and the developing fetus will become clearer.

Polycystic ovary syndrome
Females with the polycystic ovary syndrome (PCOS) represent an exception to the general findings of less prevalent/less severe OSA compared to males. PCOS is the most common endocrine disorder in females of reproductive age, and is characterised by hyperandrogenism, obesity, insulin resistance and OSA [59]. Some studies reported a worse metabolic profile in PCOS+OSA than in PCOS without OSA. However, a recent meta-analysis underlined the difficulty in interpretation of available data, since the confounding effect of obesity cannot be ruled out and more studies are needed [60]. A positive effect of CPAP on metabolic variables has been reported in this group of patients [61].

Obesity
Patients with severe obesity, who are candidates for bariatric surgery include more females than males. Large improvements in both OSA and diabetes are common after bariatric surgery [62]. OSA has been associated with worse metabolic profile in patients with morbid obesity, independently of BMI or type 2 diabetes mellitus [63]. In females on a waiting list for bariatric surgery with polysomnographically documented OSA, pharyngeal collapsibility correlated with the degree of insulin resistance [64]. CPAP use in patients with morbid obesity and OSA was associated with unchanged insulin resistance and improved glucose tolerance compared to conservative treatment in a short-term randomised controlled trial (females 72% of the sample, mean BMI 47 kg·m^{-2}) [65].

The paucity of data on males undergoing bariatric surgery does not allow conclusions to be drawn about the sex-related effects of morbid obesity.

Pathophysiology of OSA in females
The different OSA prevalence between males and females has generated interest in sex-related aspects of OSA pathophysiology. The topic is complex, encompassing anatomical and physiological features of the upper airways, the modulating effects of sex hormones on control of breathing, and sex-dependent features of fat distribution in obesity [66]. Animal models have been developed, allowing to assess sex-related differences in sleep structure [67] and acquisition of phenotypes during early development. Moreover, recent work in animal models focused on the complex action of sex steroids, not only in control of breathing, but also regarding the protective action of oestrogen against oxidative stress [68].

Anatomy of the upper airways
Upper airway dimensions are normally larger in males than in females, but similar when normalised for body size [69]. Smaller dimensions should promote collapsibility of the airways in females compared to males, but this is not the case [70]. Upper airway length was found to be higher in males than in females, and associated with higher airway collapsibility [70]. Differences between sexes in airway length are not present in the prepubertal period, but become evident in post-pubertal girls and boys, suggesting a major effect of sex hormones [71]. Upper airway length correlates with OSA severity assessed as AHI [72], and is modified by ageing, with lengthening of upper airways especially in females [73], possibly secondary to increased laxity of soft tissues [74].

Physiology of the upper airways
In OSA patients, upper airway collapsibility under passive conditions (critical closing pressure, P_{crit}) was consistently shown to be lower in females than in males [75, 76], while no sex-related difference was found in respiratory stability during sleep, evaluated as loop gain [75]. However, data on the relationship between adiposity, assessed as BMI (kg·m^{-2}), and P_{crit} differed between studies, since the slope of the relationship was similar in males and females in one study [75], and was markedly lower in females compared to males in another study of a larger sample [76]. The higher P_{crit} in males is believed to be secondary to anatomical factors, i.e. longer upper airways as previously discussed, and differences in fat distribution, since females, especially in the pre-menopausal phase, show a peripheral rather than the central pattern distribution typical of males, with lower fat deposition around the upper airways and a smaller neck circumference for a similar BMI [77].

Ventilation during sleep is similarly regulated in healthy males and females [78, 79]. However, ventilation and upper airway function in females are physiologically modulated by sex hormones. Progesterone stimulates ventilation especially when associated with oestrogen [80]. Upper airway dilator muscle function at baseline and during application of an inspiratory load during wakefulness increased in normal females during the luteal compared to the follicular phase [81]. In females without OSA, upper airway resistance during sleep was lower in the luteal compared to the follicular phase, in agreement with a "protective" effect of progesterone [82]. However, the response to inspiratory muscle loading during sleep was not accompanied by increased upper airway dilator muscle activity in normal females compared to normal males [83]. More recent data showed that compensatory responses to prolonged upper airway obstruction during non-REM sleep were more effective in obese females than in obese males [84]. Several factors may account for such differences, including a lower airflow demand secondary to lower metabolic rate in females, differences in ventilatory timing responses to obstructed upper airways [85], lower chemoresponsiveness [86] or ventilatory response to arousal [87, 88]. In addition, experimental studies in rodents suggest that females are more resistant to the detrimental effects of chronic intermittent hypoxia, an effect possibly mediated by oestrogens [89, 90]. Although some controversies still exist due to species-dependent differences [91], recent human studies suggested a role of leptin in the modulation of neural compensatory mechanisms at the upper airway level [92]. Since plasma levels of leptin are higher in females, leptin represents a potential protective factor in obese females against upper airway obstruction, possibly acting at multiple levels. The therapeutic use of intranasal leptin has been successfully tested in obese animals [93].

Recent data indicate that expression of oestrogen receptor-α is decreased in the upper airway muscles of males with OSA compared to controls, possibly contributing to changes in muscle fibre types in OSA. However, no similar data in females have been collected thus far [94].

In summary, upper airways in females are less collapsible and more stable during sleep than in males, through a variety of mechanisms which involve sex hormones but are not limited to them. More efficient active responses of upper airways during respiratory events, different body fat distribution and lower instability of respiratory drive after arousals probably contribute to the lower susceptibility to respiratory events during non-REM sleep in females. Currently, there are large efforts to physiologically phenotype OSA patients in order to personalise treatment [95]. To date, the question whether specific physiological phenotypes occur in females with OSA remains unanswered, and deserves further study.

The role of hormone replacement therapy

Approximately 25 years ago, sex steroid-based hormone replacement therapy (HRT) was no longer prescribed worldwide because of the negative results of randomised controlled trials showing that oestrogen did not confer protection against cardiovascular disease and might increase the risk of breast cancer [96]. More recently, a protective effect of oestrogen-based HRT has emerged, especially in females starting treatment early in the perimenopausal period, whereas treatment initiation at a later time did not confer any benefit [96].

As far as sleep disordered breathing is concerned, the possible protective role of HRT in post-menopausal females with OSA was assessed in studies involving small numbers of subjects. In females without symptoms of sleep disordered breathing, respiratory events during sleep were few and unaffected by oestrogen replacement therapy [97], while treatment with medroxyprogesterone acetate (MPA) improved the inspiratory flow pattern in females with airflow limitation during sleep [49, 98]. In females with OSA, the effects of HRT have been controversial. One study found no effect of MPA 30 mg·day^{-1} [99]. Another study reported improved breathing during sleep after progestin and oestrogen HRT in females with mild OSAS in post-surgical menopause [100]. CISTULLI et al. [101] found a decrease in AHI in REM sleep after HRT, while another study reported decreased AHI after treatment with oestrogens in post-menopausal females with moderate OSAS [102]. More recently, a randomised controlled trial in post-menopausal females with OSA treated with MPA after discontinuing CPAP for a few weeks showed no protective effects of MPA against respiratory events during sleep [103].

Metabolic changes

Females have a different fat distribution pattern compared to males [104]. Adipose tissue tends to be peripherally distributed in females, and centrally distributed in males, with a higher percentage of visceral fat in males compared to females with a similar BMI. Such differences reflect a role of sex hormones during the fertile age [105], tending to disappear after the menopause, and may influence the prevalence and severity of OSA in females. It has long been known that females are usually more obese than males for a similar level of OSA severity and OSA can be predicted by visceral abdominal fat in males, and by peripheral and total fat in females [106–109]. The metabolic syndrome (MetS), a cluster of risk factors for

visceral obesity and insulin resistance, is often associated with OSA in both sexes [110]. In patients with MetS and OSA, the anthropometric markers of obesity appear to be similar in males and females [111]. Finally, a recent study in young morbidly obese females awaiting bariatric surgery found that the waist-to-hip ratio was the best single predictor of AHI, even though it accounted for only 20% of total variance [112]. Therefore, menopausal status and degree of obesity interact variably in determining adipose tissue distribution and metabolic variables in females, and probably affect OSA prevalence.

The literature on OSA-associated metabolic changes does not provide satisfactory data to explore whether females show particular metabolic changes compared to males. This reflects the predominance of males in patient cohorts, and the fact that data analysis is usually adjusted for age, sex and BMI, which are the variables of interest in studies on OSA according to sex. Conversely, studies in females indicate a similar relationship between altered glucose metabolism and OSA severity as in males [113]. Females show a high frequency of respiratory events exclusively in REM sleep [114]. In diabetic patients, derangement in glycaemic control was associated only with AHI in REM, possibly due to the increased sympathetic activity typical of this sleep phase [115]. According to these data, females may be at relatively higher risk of OSA-associated glucose disturbances compared to males, despite an overall AHI which is lower than in males. To date, no study has tested such a hypothesis. In relatively young (mean age 37 years), overweight/obese subjects without comorbidities other than well-controlled hypertension or hypothyroidism, insulin resistance was documented in males, but not in females with OSA [44], in agreement with the more favourable metabolic pattern associated with peripheral distribution of adipose tissue.

In summary, knowledge on whether metabolic aspects of OSA show differences between males and females is still rather limited. Sex-related differences in adipose tissue distribution are well known, and are probably involved in both upper airway function and metabolism. Such differences tend to disappear after menopause.

Treatment of OSA/OSAHS

To date, there are few studies primarily aimed at investigating sex differences in treatment response in patients with OSA/OSAHS [8]. The "gold standard" treatment for moderate to severe OSAHS continues to be CPAP, which is applied to both sexes equally [3]. Average adherence rates do not appear to differ significantly between males and females [116, 117]. Differences in type of interface chosen, pressures required to eliminate apnoeas/hypopnoeas, humidifier use and overall treatment satisfaction do not appear to differ between the sexes when controlled for BMI, age, AHI and usage [116, 117].

With the pathophysiology of OSA in females so different from males as discussed above, it is interesting to note that very little research has been undertaken in assessing treatment algorithms in CPAP machines. Bench testing has found significant differences between commercially available CPAP devices respond to flow limitation in female patients [118] and one commercially available CPAP device addressing female-specific OSA pathophysiology was found to be as effective as standard CPAP in reducing residual flow limitation using lower mean pressures in a double-blind randomised controlled trial [119].

With exciting new work being undertaken to phenotype OSA according to the predominant physiological abnormality, it is surprising that little effort has been made to examine the prevalence of these differences and their potential impact on personalising treatment between the sexes [95, 120].

Other treatment options apart from CPAP, such as mandibular repositioning splints (MRS) and therapies applied to a minority of patients such as hypoglossal nerve stimulation and surgery for OSA/OSAHS have been trialled in both males and females, although the percentage of females is generally low in published studies [121, 122]. Two studies have suggested that MRS use is higher in females compared to males, particularly in mild OSA/OSAHS [123, 124]. Weight loss, which ideally should comprise part of the treatment of every overweight and obese person with OSA/OSAHS, can differ between the sexes. One study has shown that intensive lifestyle modifications can result in greater weight loss in females in both the short- and long-term [125], but the drop in AHI is smaller compared to that in males [126]. As discussed earler, in post-menopausal females, early studies suggested that HRT led to a reduction in OSA severity [49, 98–102], but a more recent randomised controlled study has failed to show such an effect [103], rendering this form of treatment unlikely to be specifically recommended for treating OSA at present. Future studies will have to consider variables such as age, time from beginning of menopause and type of HRT used, as well as occurrence of overweight/obesity, sleepiness and depression, as all these factors may affect the response.

Discussion

Table 1 summarises the unique characteristics of females with OSA/OSAHS. Even when using very broad definitions, OSA/OSAHS is less prevalent in females than in males in all countries. The clinical

TABLE 1 Characteristics unique to females with obstructive sleep apnoea (OSA) or OSA/hypopnoea syndrome (OSAHS) in their clinical presentation, pathophysiology, comorbidities and treatment response compared to males with OSA/OSAHS

Pathophysiology of OSA/OSAHS	Upper airway less collapsible
	Shorter airway length, which increases with age
	Lower critical closing pressure
	Subcutaneous and peripheral fat distribution
	Prolonged partial upper airway obstruction leading to increased respiratory resistance, increased end-tidal CO_2
	Lower chemoresponsiveness
	Lower metabolic rate
	Less respiratory drive instability
	Progesterone stimulates ventilation
	Higher CO_2 sensitivity and lower upper airway resistance during the luteal phase of menstrual cycle (high progesterone levels)
	Premenopausal females have lower apnoeic thresholds
In pregnancy	Reduction in airway size, fluid retention, weight gain, nasal obstruction
	Reduced functional respiratory capacity and residual volume
	Increased minute ventilation
	High progesterone leading to increased upper airway dilator muscle activity
	Enhanced chemoreceptor responsiveness
	Right-shifted oxygen dissociation curve
	Increased maternal heart rate and stroke volume
	Less time in the supine position
Clinical presentation	
Overall	More likely to present with insomnia, mood disturbances, nightmares, fatigue, lack of energy
	Greater impairment of quality of life
	Higher healthcare expenditure
	Higher rate of sick leave, impaired work performance, divorce
	Hypothyroidism more common
	Less intense snoring
Pregnancy	Increased snoring as pregnancy progresses
	Snoring/OSA associated with pregnancy-induced hypertension, intra-uterine growth retardation, hypertension and diabetes mellitus
Menopause	Clinical presentation attributed to menopause
	Doubling of OSA/OSAHS prevalence in menopause
Findings on sleep studies (polysomnography/polygraphy)	Lower AHI overall
	Shorter apnoeic episodes
	More frequent subcriterion events
	Lower proportion of supine OSA
	Higher frequency of REM-related OSA
	Longest apnoeas associated with more severe arterial oxygen desaturation
	Increased sleep fragmentation in pregnancy
Comorbidities	More systemic inflammation for given AHI
	More peripheral and subcutaneous fat distribution premenopausally
	Pharyngeal collapsibility in females awaiting bariatric surgery correlates with degree of insulin resistance
Responses to treatment	CPAP trial should be symptom-driven (AHI lower for given clinical symptoms)
	Lower CPAP pressures more common
	MRS use may be higher in mild OSA/OSAHS
	Greater voluntary weight loss sustained, but smaller relative drop in AHI

CO_2: carbon dioxide; AHI: apnoea–hypopnoea index; REM: rapid eye movement; MRS: mandibular repositioning splints.

presentation of OSA/OSAHS in females also differs from that of males, with females being more symptomatic and having a lower AHI even when controlled for age and BMI. As a consequence of the differences in clinical presentation, females with OSA/OSAHS are often underdiagnosed and undertreated compared to males. Females with OSA/OSAHS appear to have more prolonged partial upper airway obstruction as a pathophysiological hallmark of their disorder, but little work has been undertaken in modifying therapies or investigating how these differences may affect physiological phenotypes.

In summary, there are real differences between males and females in the presentation, pathophysiology, comorbidities and responses to treatment of OSA/OSAHS. These differences have not been fully elucidated and can hinder appropriate investigation and treatment due to conscious and unconscious clinical bias. In an era where personalised medicine is increasingly coming to the fore, sex differences should play the most important initial role in phenotyping patients with a view to developing new management strategies.

Conflict of interest: None declared.

References

1   Jennum P, Riha RL. Epidemiology of sleep apnoea/hypopnoea syndrome and sleep-disordered breathing. *Eur Respir J* 2009; 33: 907–914.

2   American Academy of Sleep Medicine (AASM). International Classification of Sleep Disorders, Third Edition: Diagnostic and Coding Manual. Darien, IL, AASM, 2014.

3   Riha RL. Diagnostic approaches to respiratory sleep disorders. *J Thorac Dis* 2015; 7: 1373–1384.

4   Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 1991; 14: 540–545.

5   Johns MW. Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the Epworth sleepiness scale: failure of the MSLT as a gold standard. *J Sleep Res* 2000; 9: 5–11.

6   Young T, Palta M, Dempsey J, *et al.* The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med* 1993; 328: 1230–1235.

7   Franklin KA, Lindberg E. Obstructive sleep apnea is a common disorder in the population – a review on the epidemiology of sleep apnea. *J Thorac Dis* 2015; 7: 1311–1322.

8   Theorell-Haglöw J, Miller CB, Bartlett DJ, *et al.* Gender differences in obstructive sleep apnoea, insomnia and restless legs syndrome in adults – what do we know? A clinical update. *Sleep Med Rev* 2018; 38: 28–38.

9   Wimms A, Woehrle H, Ketheeswaran S, *et al.* Obstructive sleep apnea in women: specific issues and interventions. *Biomed Res Int* 2016; 2016: 1764837.

10   Franklin KA, Sahlin C, Stenlund H, *et al.* Sleep apnoea is a common occurrence in females. *Eur Respir J* 2013; 41: 610–615.

11   Kapsimalis F, Kryger MH. Gender and obstructive sleep apnea syndrome, part 1: clinical features. *Sleep* 2002; 25: 412–419.

12   Sforza E, Chouchou F, Collet P, *et al.* Sex differences in obstructive sleep apnoea in an elderly French population. *Eur Respir J* 2011; 37: 1137–1143.

13   Levartovsky A, Dafna E, Zigel Y, *et al.* Breathing and snoring sound characteristics during sleep in adults. *J Clin Sleep Med* 2016; 12: 375–384.

14   Greenberg-Dotan S, Reuveni H, Simon-Tuval T, *et al.* Gender differences in morbidity and health care utilization among adult obstructive sleep apnea patients. *Sleep* 2007; 30: 1173–1180.

15   Gabbay IE, Lavie P. Age- and gender-related characteristics of obstructive sleep apnea. *Sleep Breath* 2012; 16: 453–460.

16   Sjösten N, Kivimäki M, Oksanen T, *et al.* Obstructive sleep apnoea syndrome as a predictor of work disability. *Respir Med* 2009; 103: 1047–1055.

17   Rod NH, Kjeldgård L, Åkerstedt T, *et al.* Sleep apnea, disability pensions, and cause-specific mortality: a Swedish nationwide register linkage study. *Am J Epidemiol* 2017; 186: 709–718.

18   Tasbakan MS, Gunduz C, Pirildar S, *et al.* Quality of life in obstructive sleep apnea is related to female gender and comorbid insomnia. *Sleep Breath* 2018; 22: 1013–1020.

19   Grunstein RR, Stenlöf K, Hedner JA, *et al.* Impact of self-reported sleep-breathing disturbances on psychosocial performance in the Swedish Obese Subjects (SOS) Study. *Sleep* 1995; 18: 635–643.

20   Sjösten N, Vahtera J, Salo P, *et al.* Increased risk of lost workdays prior to the diagnosis of sleep apnea. *Chest* 2009; 136: 130–136.

21   Kulkas A, Duce B, Leppänen T, *et al.* Gender differences in severity of desaturation events following hypopnea and obstructive apnea events in adults during sleep. *Physiol Meas* 2017; 38: 1490–1502.

22   Young T, Hutton R, Finn L, *et al.* The gender bias in sleep apnea diagnosis. Are women missed because they have different symptoms? *Arch Intern Med* 1996; 156: 2445–2451.

23   Svensson M, Franklin KA, Theorell-Haglöw J, *et al.* Daytime sleepiness relates to snoring independent of the apnea-hypopnea index in women from the general population. *Chest* 2008; 134: 919–924.

24   McNicholas WT, Bonsignore MR, Lévy P, *et al.* Mild obstructive sleep apnoea: clinical relevance and approaches to management. *Lancet Respir Med* 2016; 4: 826–834.

25   Polo-Kantola P, Rauhala E, Helenius H, *et al.* Breathing during sleep in menopause: a randomized, controlled, crossover trial with estrogen therapy. *Obstet Gynecol* 2003; 102: 68–75.

26   Anttalainen U, Saaresranta T, Kalleinen N, *et al.* Gender differences in age and BMI distributions in partial upper airway obstruction during sleep. *Respir Physiol Neurobiol* 2007; 159: 219–226.

27   Guilleminault C, Stoohs R, Clerk A, *et al.* A cause of excessive daytime sleepiness. The upper airway resistance syndrome. *Chest* 1993; 104: 781–787.

28   Mohsenin V. Gender differences in the expression of sleep-disordered breathing: role of upper airway dimensions. *Chest* 2001; 120: 1442–1447.

29   Rauhala E, Himanen SL, Saastamoinen A, *et al.* Prolonged spiking in the Emfit sensor in patients with sleep-disordered breathing is characterized by increase in transcutaneous carbon dioxide. *Physiol Meas* 2007; 28: 1163–1173.

30   Rimpilä V, Saaresranta T, Huhtala H, *et al.* Transcutaneous CO_2 plateau as set-point for respiratory drive during upper airway flow-limitation. *Respir Physiol Neurobiol* 2014; 191: 44–51.

31   Himanen SL, Martikkala L, Sulkamo S, *et al.* Prolonged partial obstruction during sleep is a NREM phenomenon. *Respir Physiol Neurobiol* 2018; 255: 43–49.

32   Anttalainen U, Saaresranta T, Kalleinen N, *et al.* CPAP adherence and partial upper airway obstruction during sleep. *Sleep Breath* 2007; 11: 171–176.

33   Polo O, Brissaud L, Fraga J, *et al.* Partial upper airway obstruction in sleep after uvulopalatopharyngoplasty. *Arch Otolaryngol Head Neck Surg* 1989; 115: 1350–1354.

34   Calero G, Farre R, Ballester E, *et al.* Physiological consequences of prolonged periods of flow limitation in patients with sleep apnea hypopnea syndrome. *Respir Med* 2006; 100: 813–817.

35   Meurice JC, Paquereau J, Denjean A, *et al.* Influence of correction of flow limitation on continuous positive airway pressure efficiency in sleep apnoea/hypopnoea syndrome. *Eur Respir J* 1998; 11: 1121–1127.

36   Wang D, Piper AJ, Yee BJ, *et al.* Hypercapnia is a key correlate of EEG activation and daytime sleepiness in hypercapnic sleep disordered breathing patients. *J Clin Sleep Med* 2014; 10: 517–522.

37   Morisson F, Décary A, Petit D, *et al.* Daytime sleepiness and EEG spectral analysis in apneic patients before and after treatment with continuous positive airway pressure. *Chest* 2001; 119: 45–52.

38   Gouveris H, Bahr K, Jahn C, *et al.* The apnea-hypopnea index underestimates systemic inflammation in women with sleep-disordered breathing. *J Womens Health* 2018; 27: 920–926.

39   Ljunggren M, Lindberg E, Franklin KA, *et al.* Obstructive sleep apnea during rapid eye movement sleep is associated with early signs of atherosclerosis in women. *Sleep* 2018; 41: zsy099.

40   Strausz S, Havulinna AS, Tuomi T, *et al.* Obstructive sleep apnoea and the risk for coronary heart disease and type 2 diabetes: a longitudinal population-based study in Finland. *BMJ Open* 2018; 8: e022752.

41   Anttalainen U, Grote L, Fietze I, *et al.* Insomnia symptoms combined with nocturnal hypoxia associate with cardiovascular comorbidity in the European sleep apnoea cohort (ESADA). *Sleep Breath* 2019; 23: 805–814.

42   Saaresranta T, Hedner J, Bonsignore MR, *et al.* Clinical phenotypes and comorbidity in European sleep apnoea patients. *PLoS One* 2016; 11: e0163439.

43   Geovanini GR, Wang R, Weng J, *et al.* Association between obstructive sleep apnea and cardiovascular risk factors: variation by age, sex, and race. The Multi-Ethnic Study of Atherosclerosis. *Ann Am Thorac Soc* 2018; 15: 970–977.

44   Temple KA, Leproult R, Morselli L, *et al.* Sex differences in the impact of obstructive sleep apnea on glucose metabolism. *Front Endocrinol* 2018; 9: 376.

45   Bixler EO, Vgontzas AN, Lin HM, *et al.* Prevalence of sleep-disordered breathing in women: effects of gender. *Am J Respir Crit Care Med* 2001; 163: 608–613.

46   Young T, Finn L, Austin D, *et al.* Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. *Am J Respir Crit Care Med* 2003; 167: 1181–1185.

47   Anttalainen U, Saaresranta T, Aittokallio J, *et al.* Impact of menopause on the manifestation and severity of sleep-disordered breathing. *Acta Obstet Gynecol Scand* 2006; 85: 1381–1388.

48   Rowley JA, Zhou XS, Diamond MP, *et al.* The determinants of the apnea threshold during NREM sleep in normal subjects. *Sleep* 2006; 29: 95–103.

49   Saaresranta T, Aittokallio T, Polo-Kantola P, *et al.* Effect of medroxyprogesterone on inspiratory flow shapes during sleep in postmenopausal women. *Respir Physiol Neurobiol* 2003; 134: 131–143.

50   Gao CC, Kapoor E, Lipford MC, *et al.* Association of vasomotor symptoms and sleep apnea risk in midlife women. *Menopause* 2018; 25: 391–398.

51   Huang T, Lin BM, Redline S, *et al.* Type of menopause, age at menopause, and risk of developing obstructive sleep apnea in postmenopausal women. *Am J Epidemiol* 2018; 187: 1370–1379.

52   LoMauro A, Aliverti A. Respiratory physiology of pregnancy: physiology masterclass. *Breathe* 2015; 11: 297–301.

53   Tan EK, Tan EL. Alterations in physiology and anatomy during pregnancy. *Best Pract Res Clin Obstet Gynaecol* 2013; 27: 791–802.

54   Izci-Balserak B, Keenan BT, Corbitt C, *et al.* Changes in sleep characteristics and breathing parameters during sleep in early and late pregnancy. *J Clin Sleep Med* 2018; 14: 1161–1168.

55   Dunietz GL, Shedden K, Schisterman EF, *et al.* Associations of snoring frequency and intensity in pregnancy with time-to-delivery. *Paediatr Perinat Epidemiol* 2018; 32: 504–511.

56   Salameh M, Lee J, Palomaki G, *et al.* Snoring and markers of fetal and placental wellbeing. *Clin Chim Acta* 2018; 485: 139–143.

57   Louis JM, Koch MA, Reddy UM, *et al.* Predictors of sleep-disordered breathing in pregnancy. *Am J Obstet Gynecol* 2018; 218: 521.e1–521.e12.

58   Warland J, Dorrian J, Morrison JL, *et al.* Maternal sleep during pregnancy and poor fetal outcomes: a scoping review of the literature with meta-analysis. *Sleep Med Rev* 2018; 41: 197–219.

59   Kahal H, Kyrou I, Tahrani AA, *et al.* Obstructive sleep apnoea and polycystic ovary syndrome: a comprehensive review of clinical interactions and underlying pathophysiology. *Clin Endocrinol* 2017; 87: 313–319.

60   Kahal H, Kyrou I, Uthman O, *et al.* The association between obstructive sleep apnea and metabolic abnormalities in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Sleep* 2018; 41: zsy085.

61   Tasali E, Chapotot F, Leproult R, *et al.* Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2011; 96: 365–374.

62   Miras AD, Kamocka A, Patel D, *et al.* Obesity surgery makes patients healthier and more functional: real world results from the United Kingdom National Bariatric Surgery Registry. *Surg Obes Relat Dis* 2018; 14: 1033–1040.

63   Gasa M, Salord N, Fortuna AM, *et al.* Obstructive sleep apnoea and metabolic impairment in severe obesity. *Eur Respir J* 2011; 38: 1089–1097.

64   Llanos OL, Galiatsatos P, Guzmán-Vélez E, *et al.* Pharyngeal collapsibility during sleep is elevated in insulin-resistant females with morbid obesity. *Eur Respir J* 2016; 47: 1718–1726.

65   Salord N, Fortuna AM, Monasterio C, *et al.* A randomized controlled trial of continuous positive airway pressure on glucose tolerance in obese patients with obstructive sleep apnea. *Sleep* 2016; 39: 35–41.

66   Lozo T, Komnenov D, Badr MS, *et al.* Sex differences in sleep disordered breathing in adults. *Respir Physiol Neurobiol* 2017; 245: 65–75.

67   Mong JA, Cusmano DM. Sex differences in sleep: impact of biological sex and sex steroids. *Philos Trans R Soc Lond B Biol Sci* 2016; 371: 20150110.

68   Boukari R, Laouafa S, Ribon-Demars A, *et al.* Ovarian steroids act as respiratory stimulant and antioxidant against the causes and consequences of sleep-apnea in women. *Respir Physiol Neurobiol* 2017; 239: 46–54.

69   Brown IG, Zamel N, Hoffstein V. Pharyngeal cross-sectional area in normal men and women. *J Appl Physiol* 1986; 61: 890–895.

70   Malhotra A, Huang Y, Fogel RB, *et al.* The male predisposition to pharyngeal collapse: importance of airway length. *Am J Respir Crit Care Med* 2002; 166: 1388–1395.

71   Ronen O, Malhotra A, Pillar G. Influence of gender and age on upper-airway length during development. *Pediatrics* 2007; 120: e1028–e1034.

72   Segal Y, Malhotra A, Pillar G. Upper airway length may be associated with the severity of obstructive sleep apnea syndrome. *Sleep Breath* 2008; 12: 311–316.

73   Malhotra A, Huang Y, Fogel R, *et al.* Aging influences on pharyngeal anatomy and physiology: the predisposition to pharyngeal collapse. *Am J Med* 2006; 119: 72.e9–72.e14.

74   Shigeta Y, Ogawa T, Venturin J, *et al.* Gender- and age-based differences in computerized tomographic measurements of the oropharynx. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008; 106: 563–570.

75   Jordan AS, Wellman A, Edwards JK, *et al.* Respiratory control stability and upper airway collapsibility in men and women with obstructive sleep apnea. *J Appl Physiol* 2006; 99: 2020–2027.

76   Kirkness JP, Schwartz AR, Schneider H, *et al.* Contribution of male sex, age, and obesity to mechanical instability of the upper airway during sleep. *J Appl Physiol* 2008; 104: 1618–1624.

77   Schwartz AR, Patil SP, Squier S, *et al.* Obesity and upper airway control during sleep. *J Appl Physiol* 2010; 108: 430–435.

78   White DP, Weil JV, Zwillich CW. Metabolic rate and breathing during sleep. *J Appl Physiol* 1985; 59: 384–391.

79   Douglas NJ, White DP, Pickett CK, *et al.* Respiration during sleep in normal man. *Thorax* 1982; 37: 840–844.

80   Regensteiner JG, Woodard WD, Hagerman DD, *et al.* Combined effects of female hormones and metabolic rate on ventilatory drives in women. *J Appl Physiol* 1989; 66: 808–813.

81   Popovic RM, White DP. Upper airway muscle activity in normal women: influence of hormonal status. *J Appl Physiol* 1998; 84: 1055–1062.

82   Driver HS, McLean H, Kumar DV, *et al.* The influence of the menstrual cycle on upper airway resistance and breathing during sleep. *Sleep* 2005; 28: 449–456.

83   Pillar G, Malhotra A, Fogel R, *et al.* Airway mechanics and ventilation in response to resistive loading during sleep. Influence of gender. *Am J Respir Crit Care Med* 2000; 162: 1627–1632.

84   Chin CH, Kirkness JP, Patil SP, *et al.* Compensatory responses to upper airway obstruction in obese apneic men and women. *J Appl Physiol* 2012; 112: 403–410.

85   Schneider H, Krishnan V, Pichard LE, *et al.* Inspiratory duty cycle responses to flow limitation predict nocturnal hypoventilation. *Eur Respir J* 2009; 33: 1068–1076.

86   Zhou XS, Shahabuddin S, Zahn BR, *et al.* Effect of gender on the development of hypocapnic apnea/hypopnea during NREM sleep. *J Appl Physiol* 2000; 89: 192–199.

87   Jordan AS, Eckert DJ, Catcheside PG, *et al.* Ventilatory response to brief arousal from non-rapid eye movement sleep is greater in men than in women. *Am J Respir Crit Care Med* 2003; 168: 1512–1519.

88   Jordan AS, McEvoy RD, Edwards JK, *et al.* The influence of gender and upper airway resistance on the ventilatory response to arousal in obstructive sleep apnoea in humans. *J Physiol* 2004; 558: 993–1004.

89   O'Halloran KD, Lewis P, McDonald F. Sex, stress and sleep apnoea: decreased susceptibility to upper airway muscle dysfunction following intermittent hypoxia in females. *Respir Physiol Neurobiol* 2017; 245: 76–82.

90   Laouafa S, Ribon-Demars A, Marcouiller F, *et al.* Estradiol protects against cardiorespiratory dysfunctions and oxidative stress in intermittent hypoxia. *Sleep* 2017; 40: zxs104.

91   Imayama I, Prasad B. Role of leptin in obstructive sleep apnea. *Ann Am Thorac Soc* 2017; 14: 1607–1621.

92   Shapiro SD, Chin CH, Kirkness JP, *et al.* Leptin and the control of pharyngeal patency during sleep in severe obesity. *J Appl Physiol* 2014; 116: 1334–1341.

93   Berger S, Pho H, Fleury-Curado T, *et al.* Intranasal leptin relieves sleep-disordered breathing in mice with diet-induced obesity. *Am J Respir Crit Care Med* 2019; 199: 773–783.

94   Chen HH, Lu J, Guan YF, *et al.* Estrogen/ERR-α signaling axis is associated with fiber-type conversion of upper airway muscles in patients with obstructive sleep apnea hypopnea syndrome. *Sci Rep* 2016; 6: 27088.

95   Bonsignore MR, Suarez Giron MC, Marrone O, *et al.* Personalised medicine in sleep respiratory disorders: focus on obstructive sleep apnoea diagnosis and treatment. *Eur Respir Rev* 2017; 26: 170069.

96   Lobo RA, Pickar JH, Stevenson JC, *et al.* Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. *Atherosclerosis* 2016; 254: 282–290.

97   Polo-Kantola P, Erkkola R, Irjala K, *et al.* Effect of short-term transdermal estrogen replacement therapy on sleep: a randomized, double-blind crossover trial in postmenopausal women. *Fertil Steril* 1999; 71: 873–880.

98   Saaresranta T, Polo-Kantola P, Rauhala E, *et al.* Medroxyprogesterone in postmenopausal females with partial upper airway obstruction during sleep. *Eur Respir J* 2001; 18: 989–995.

99   Block AJ, Wynne JW, Boysen PG, *et al.* Menopause, medroxyprogesterone and breathing during sleep. *Am J Med* 1981; 70: 506–510.

100   Pickett CK, Regensteiner JG, Woodard WD, *et al.* Progestin and estrogen reduce sleep-disordered breathing in postmenopausal women. *J Appl Physiol* 1989; 66: 1656–1661.

101   Cistulli PA, Barnes DJ, Grunstein RR, *et al.* Effect of short-term hormone replacement in the treatment of obstructive sleep apnoea in postmenopausal women. *Thorax* 1994; 49: 699–702.

102   Manber R, Kuo TF, Cataldo N, *et al.* The effects of hormone replacement therapy on sleep-disordered breathing in postmenopausal women: a pilot study. *Sleep* 2003; 26: 163–168.

103   Anttalainen U, Saaresranta T, Vahlberg T, *et al.* Short-term medroxyprogesterone acetate in postmenopausal women with sleep-disordered breathing: a placebo-controlled, randomized, double-blind, parallel-group study. *Menopause* 2014; 21: 361–368.

104   White UA, Tchoukalova YD. Sex dimorphism and depot differences in adipose tissue function. *Biochim Biophys Acta* 2014; 1842: 377–392.

105   Geer EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. *Gender Med* 2009; 6: Suppl. 1, 60–75.

106   Kritikou I, Basta M, Tappouni R, *et al.* Sleep apnoea and visceral adiposity in middle-aged male and female subjects. *Eur Respir J* 2013; 41: 601–609.

107 Lubrano C, Saponara M, Barbaro G, *et al.* Relationships between body fat distribution, epicardial fat and obstructive sleep apnea in obese patients with and without metabolic syndrome. *PLoS One* 2012; 7: e47059.

108 Harada Y, Oga T, Chihara Y, *et al.* Differences in associations between visceral fat accumulation and obstructive sleep apnea by sex. *Ann Am Thorac Soc* 2014; 11: 383–391.

109 Simpson L, Mukherjee S, Cooper MN, *et al.* Sex differences in the association of regional fat distribution with the severity of obstructive sleep apnea. *Sleep* 2010; 33: 467–474.

110 Gaines J, Vgontzas AN, Fernandez-Mendoza J, *et al.* Obstructive sleep apnea and the metabolic syndrome: the road to clinically-meaningful phenotyping, improved prognosis, and personalized treatment. *Sleep Med Rev* 2018; 42: 211–219.

111 Mazzuca E, Battaglia S, Marrone O, *et al.* Gender-specific anthropometric markers of adiposity, metabolic syndrome and visceral adiposity index (VAI) in patients with obstructive sleep apnea. *J Sleep Res* 2014; 23: 13–21.

112 Gasa M, López-Padrós C, Monasterio C, *et al.* Anthropometrical phenotypes are important when explaining obstructive sleep apnea in female bariatric cohorts. *J Sleep Res* 2019: e12830.

113 Theorell-Haglöw J, Berne C, Janson C, *et al.* Obstructive sleep apnoea is associated with decreased insulin sensitivity in females. *Eur Respir J* 2008; 31: 1054–1060.

114 Koo BB, Patel SR, Strohl K, *et al.* Rapid eye movement-related sleep-disordered breathing.: influence of age and gender. *Chest* 2008; 134: 1156–1161.

115 Grimaldi D, Beccuti G, Touma C, *et al.* Association of obstructive sleep apnea in rapid eye movement sleep with reduced glycemic control in type 2 diabetes: therapeutic implications. *Diabetes Care* 2014; 37: 355–363.

116 Jayaraman G, Majid H, Surani S, *et al.* Influence of gender on continuous positive airway pressure requirements in patients with obstructive sleep apnea syndrome. *Sleep Breath* 2011; 15: 781–784.

117 Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. *Lancet* 2014; 383: 736–747.

118 Isetta V, Montserrat JM, Santano R, *et al.* Novel approach to simulate sleep apnea patients for evaluating positive pressure therapy devices. *PLoS One* 2016; 11: e0151530.

119 McArdle N, King S, Shepherd K, *et al.* Study of a novel APAP algorithm for the treatment of obstructive sleep apnea in women. *Sleep* 2015; 38: 1775–1781.

120 Eckert DJ. Phenotypic approaches to obstructive sleep apnoea – new pathways for targeted therapy. *Sleep Med Rev* 2018; 37: 45–59.

121 Wray CM, Thaler ER. Hypoglossal nerve stimulation for obstructive sleep apnea: a review of the literature. *World J Otorhinolaryngol Head Neck Surg* 2016; 2: 230–233.

122 Garg RK, Afifi AM, Sanchez R, *et al.* Obstructive sleep apnea in adults: the role of upper airway and facial skeletal surgery. *Plast Reconstr Surg* 2016; 138: 889–898.

123 Marklund M, Stenlund H, Franklin KA. Mandibular advancement devices in 630 men and women with obstructive sleep apnea and snoring: tolerability and predictors of treatment success. *Chest* 2004; 125: 1270–1278.

124 Vecchierini MF, Attali V, Collet JM, *et al.* Sex differences in mandibular repositioning device therapy effectiveness in patients with obstructive sleep apnea syndrome. *Sleep Breath* 2019; 23: 837–848.

125 Newman AB, Foster G, Givelber R, *et al.* Progression and regression of sleep-disordered breathing with changes in weight: the Sleep Heart Health Study. *Arch Intern Med* 2005; 165: 2408–2413.

126 Kuna ST, Reboussin DM, Borradaile KE, *et al.* Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. *Sleep* 2013; 36: 641–649A.